Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Muzastotug and Pembrolizumab in Locally Advanced Colorectal Cancer
NCT06846268Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of muzastotug in colorectal cancer (CRC), sponsored by National University Hospital. Primary endpoint: Rate of Major Pathologic Response up to 4 months. Started Apr 2025; status: recruiting.
02
Drugs
muzastotug
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06846268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846268.